Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer
ADC / XDCAstraZeneca

Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer

Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer
BayerCancer

Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer

Clinical trial resultsNASDAQ: SNY

Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication
Eli LillyHot targets

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication

Show More